Ssion on 23 November 2013, Dr Anthony Oyekunle presenting on behalf of his colleague, Dr

Ssion on 23 November 2013, Dr Anthony Oyekunle presenting on behalf of his colleague, Dr MA Durosinmi with the Obafemi Awolowo University, Ile-Ife, Nigeria, sought to bring into focus the challenges linked with managing myelodysplastic syndromes (MDS) in Africa inside the face of inadequate diagnostic choices and challenges of classification and provision of proper therapy. He observed that MDS aren’t uncommon in Africa, but that the clinical attributes are related to published reports from other components of the planet. Diagnosis is restricted to morphologic examination of peripheral blood and marrow cells, while facilities like cytogenetics and immunophenotyping of tumour cells are extremely restricted, specially within the majority of SSA countries. FAB classification will be the norm in the majority of the centres. The more all-encompassing WHO classification method was limited to a number of centres inside the North and South Africa, thus generating stratification of sufferers into threat groups based on International Prognostic Scoring System impossible. Dr Durosinmi expressed the hope that efforts could be produced to upgrade levels of haematologypathology laboratories in SSA to hightech standards with facilities for IHC, immunophenotyping, cytogenetics, and molecular pathology strategies, so as to allow improved characterisations of haematological neoplasia, like MDS. Chronic myeloid leukaemia In his presentation at the Free of charge Communication Of Abstracts II of 22 November 2013, titled `Survivorship in Nigeria Individuals With Chronic Myeloid Leukemia: A study of 527 Patients More than 10 years’, Dr Anthony Oyekunle on the Obafemi University Teaching Hospital, Ile-Ife, Nigeria, observed that the advent from the tyrosine kinase inhibitor (TKI) had markedly changed the prognostic outlook for patients with Ph+ andor BCR-ABL1+ chronic myeloid leukaemia (CML). The study was created to assess the OS of Nigerian sufferers with CML on imatinib therapy. All CML individuals treated in the institution on imatinib from July 2003 to June 2013 were reviewed. The median age of the patients was 37 PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21338496 (range: 107) years, plus the gender distribution was malefemale = 320207; 472 have been in chronic, 47 in accelerated, and seven in blast phase; 442 sufferers are alive by June 2013, with median survival of 105.7 (95 CI, 91.519.9) months; and OS at a single, two, and five years have been 95 , 90 , and 75 , respectively, with the survival in CP being significantly better (p 0.0001) compared with those in AP or BP (107.3, 74.7, and 53.7 months, respectively). Soon after ten years of follow-up, imatinib MedChemExpress AG 879 monotherapy continues to provide impressive survival outcomes among Nigerian CML patients. Nonetheless, the patients have no access to second line TKIs, possibly accounting for the reduced survival when compared with outcomes in Western populations. Within the query period, Dr Oyekunle described a number of complications of hyperleucocytosis that was typical at presentation, regularly connected with organ impairment, including vision and hearing loss, often reversible by lowering of your white blood count. In a poster presentation on 21 November 2013 titled `Unusual Presentations of Chronic Myeloid Leukaemia’, Dr Amma Benneh-Akwasi Kuma described a variety of patients presented with hearing loss and priapism as uncommon presentation of CML. They constituted eight.3 from the patients seen at the centre. These manifestations of hyperleucocytosis related organ failure constitute a supply of compromise of high quality of life that may be prevented by ea.